Breaking News

Apr 9, 20211 min read

KRAS Kickers featured at AACR

American Association for Cancer Research (AACR) is the first and largest cancer research organization dedicated to accelerating the...

Mar 25, 20213 min read

Treatment with the KRAS G12C inhibitor adagrasib showed clinical activity in patients with advanced non–small cell lung cancer (NSCLC)...

Mar 24, 20213 min read

Clinical activity with a second drug inhibiting KRASG12C confirms its role as a therapeutic target in patients with advanced...

Mar 11, 202114 min read

Eli Lilly and Company (NYSE: LLY) today announced that data from programs across its oncology portfolio and pipeline will be presented at...

Mar 11, 20212 min read

Eli Lilly has rejoined the KRAS race months after toxicity forced it to dump its first candidate. The Big Pharma is set to enter phase 1...

Mar 6, 20217 min read

David Cox Forty years after the mutant genes that cause the deadliest cancers were discovered, drugs that target them could be approved...

Feb 5, 20214 min read

Gina Kolata No drug could touch a quivering protein implicated in a variety of tumors. Then one chemist saw an opening. After 40 years of...

Jan 25, 20213 min read

IASLC Exciting New Research to be Presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer’s...

Jan 19, 202123 min read

KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer (NSCLC). It was previously thought to be an...

Upstage Lung Cancer heard the power of hope to kick cancer from Terri Conneran

Brief Summary “Up to 250 patients from anywhere in the United States can remotely consent and participate to have plasma drawn locally...

Rev Med reports out on the 46% of the pancreatic cancer patients who were enrolled in NCT05379985 (54% of patients are NSLC or other...